NASDAQ:JYNT Joint (JYNT) Stock Price, News & Analysis $10.77 -0.24 (-2.18%) Closing price 04:00 PM EasternExtended Trading$10.75 -0.02 (-0.19%) As of 05:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Joint Stock (NASDAQ:JYNT) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Joint alerts:Sign Up Key Stats Today's Range$10.46▼$10.9750-Day Range$10.70▼$12.5152-Week Range$9.58▼$13.47Volume38,218 shsAverage Volume58,575 shsMarket Capitalization$164.78 millionP/E RatioN/ADividend YieldN/APrice Target$16.33Consensus RatingBuy Company Overview The Joint Corp. operates and franchises chiropractic clinics in the United States. The company operates in two segments, Corporate Clinics and Franchise Operations. The Joint Corp. was incorporated in 2010 and is headquartered in Scottsdale, Arizona. Read More Joint Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks69th Percentile Overall ScoreJYNT MarketRank™: Joint scored higher than 69% of companies evaluated by MarketBeat, and ranked 270th out of 936 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingJoint has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageJoint has only been the subject of 1 research reports in the past 90 days.Read more about Joint's stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth381.82% Earnings GrowthEarnings for Joint are expected to grow by 381.82% in the coming year, from $0.11 to $0.53 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Joint is -32.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Joint is -32.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioJoint has a P/B Ratio of 8.98. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted3.91% of the float of Joint has been sold short.Short Interest Ratio / Days to CoverJoint has a short interest ratio ("days to cover") of 9.Change versus previous monthShort interest in Joint has recently increased by 7.37%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldJoint does not currently pay a dividend.Dividend GrowthJoint does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted3.91% of the float of Joint has been sold short.Short Interest Ratio / Days to CoverJoint has a short interest ratio ("days to cover") of 9.Change versus previous monthShort interest in Joint has recently increased by 7.37%, indicating that investor sentiment is decreasing significantly. News and Social Media2.0 / 5News Sentiment0.66 News SentimentJoint has a news sentiment score of 0.66. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 25 news articles for Joint this week, compared to 3 articles on an average week. Company Ownership3.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Joint insiders have not sold or bought any company stock.Percentage Held by Insiders27.90% of the stock of Joint is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions76.88% of the stock of Joint is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Joint's insider trading history. Receive JYNT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Joint and its competitors with MarketBeat's FREE daily newsletter. Email Address JYNT Stock News HeadlinesJoint Corp’s Earnings Call: Mixed Outlook Amid Growth and ChallengesAugust 13 at 5:05 AM | msn.comThe Joint Corp. (NASDAQ:JYNT) Q2 2025 Earnings Call TranscriptAugust 12 at 7:03 PM | msn.comThe stealth altcoin the financial world is underestimatingThis DeFi project could soar next When altcoin season fully kicks in—which the data suggests is happening RIGHT NOW—this project is poised to see massive moves.... The smart money is already positioning.August 14 at 2:00 AM | Crypto 101 Media (Ad)The Joint Corp. Delays Form 10-Q FilingAugust 12 at 8:29 AM | tipranks.comRakovina Therapeutics and NanoPalm Ltd. Sign Letter of Intent to Form Joint Venture Leveraging AI-Discovered Oncology Therapies and Novel Lipid Nanoparticle Delivery TechnologiesAugust 12 at 5:00 AM | globenewswire.comRoth MKM Sticks to Its Buy Rating for Joint (JYNT)August 12 at 4:39 AM | theglobeandmail.comHead to Head Survey: Joint (NASDAQ:JYNT) vs. Centene (NYSE:CNC)August 11 at 2:55 AM | americanbankingnews.comA Look At The Intrinsic Value Of The Joint Corp. (NASDAQ:JYNT)August 9, 2025 | finance.yahoo.comSee More Headlines JYNT Stock Analysis - Frequently Asked Questions How have JYNT shares performed this year? Joint's stock was trading at $10.63 at the beginning of the year. Since then, JYNT shares have increased by 1.3% and is now trading at $10.77. How were Joint's earnings last quarter? The Joint Corp. (NASDAQ:JYNT) issued its quarterly earnings results on Thursday, August, 7th. The company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.07) by $0.01. The firm had revenue of $13.27 million for the quarter, compared to the consensus estimate of $13.32 million. Joint had a positive trailing twelve-month return on equity of 0.67% and a negative net margin of 7.02%. Read the conference call transcript. Is Joint buying back stock? Joint's board authorized a stock repurchase plan on Thursday, June 5th 2025, which authorizes the company to repurchase $5,000,000 in shares, according to EventVestor. This means that the company could repurchase up to 2.7% of its stock through open market purchases. Stock repurchase plans are typically a sign that the company's board of directors believes its stock is undervalued. When did Joint IPO? Joint (JYNT) raised $20 million in an IPO on Tuesday, November 11th 2014. The company issued 3,000,000 shares at $6.50 per share. Roth Capital Partners and Feltl and Company acted as the underwriters for the IPO and Sanders Morris Harris was co-manager. Who are Joint's major shareholders? Joint's top institutional shareholders include Geode Capital Management LLC (2.26%), O Brien Greene & Co. Inc (1.09%), Verus Capital Partners LLC (0.73%) and Russell Investments Group Ltd. (0.67%). View institutional ownership trends. How do I buy shares of Joint? Shares of JYNT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Joint own? Based on aggregate information from My MarketBeat watchlists, some other companies that Joint investors own include American Water Works (AWK), Humana (HUM), Waste Connections (WCN), Voyager Therapeutics (VYGR), The RMR Group (RMR), AU Optronics (AUOTY) and DiamondRock Hospitality (DRH). Company Calendar Last Earnings8/07/2025Today8/14/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - HMO Sub-IndustryTrading Current SymbolNASDAQ:JYNT CIK1612630 Webwww.thejoint.com Phone(480) 245-5960Fax480-513-7989Employees320Year FoundedN/APrice Target and Rating Average Price Target for Joint$16.33 High Price Target$18.00 Low Price Target$15.00 Potential Upside/Downside+51.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($0.33) Trailing P/E RatioN/A Forward P/E Ratio98.32 P/E GrowthN/ANet Income-$8.53 million Net Margins-7.02% Pretax Margin1.21% Return on Equity0.67% Return on Assets0.16% Debt Debt-to-Equity RatioN/A Current Ratio1.59 Quick Ratio1.59 Sales & Book Value Annual Sales$51.90 million Price / Sales3.19 Cash Flow$0.64 per share Price / Cash Flow16.95 Book Value$1.20 per share Price / Book9.01Miscellaneous Outstanding Shares15,300,000Free Float11,033,000Market Cap$165.47 million OptionableOptionable Beta1.53 Social Links A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free Report This page (NASDAQ:JYNT) was last updated on 8/14/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredBut this $20 American company could control the secretThe "Impossible" Chip That Runs on Pure Light Google's quantum computer shocked the world... but China DEMO...The Oxford Club | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding The Joint Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Joint With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.